Company Data

ARCA biopharma Inc.

Ticker
ABIO
Price Target
Refer to Report
Volume
32.8M
52wk Range
$1.56 - $4.49
Advanced Market Data

Overview

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company’s product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy